MRSA and Destiny Pharma logo
Current news

4th August 2014: Angel CoFund join UK investors in £2.8m investment for Superbug Killing Company

Innovative UK pharmaceutical company, Destiny Pharma, completes investment round to fund a landmark clinical trial of a new drug designed to combat antibiotic resistant bacteria

4th August 2014, Brighton: UK Clinical stage pharmaceutical company, Destiny Pharma, can today announce its successful investment round of over £2.8 million to fund a landmark clinical trial for its lead drug, XF-73, to prevent post-surgical Staphylococcal infections. The Angel CoFund, (the £100m fund for small and medium sized British businesses, with Government backing), invested in Destiny Pharma, alongside other UK investors.

Infection from bacteria remains a worrying complication for hospital admissions. One of the most common causes of infection is the bacterium Staphylococcus aureus (SA). XF-73 is a 'nasal decolonisation' treatment intended to clear SA bacteria from the nostrils of carriers, to prevent post-surgical SA infection. It has been proven to be an effective drug for killing both SA and the drug-resistant form of the bacteria, MRSA.

Antibiotic resistance is of growing concern with David Cameron warning that we may be heading into a post-antibiotic era akin to the 'medical dark ages'. In July this year, he announced an independent review on the subject with a view to make recommendations as to how to stimulate the development of new antibiotics, which will be presented to the G7. Public awareness and support is behind this drive for new antibiotics, demonstrated by Antibiotic Resistance winning the public vote for the £10m Longitude Prize.

The US government is currently funding an on-going clinical trial of XF-73, which further highlights the global interest in Destiny Pharma and its approach to ensure the drug is adopted across all major markets. In July 2014, the US Infective Disease Society of America published new recommendations for the prevention of SA/MRSA infection, which will now include a highest-grade recommendation for nasal decolonisation of all Intensive Care Unit patients to reduce infection.

Dr Bill Love, CEO of Destiny Pharma commented: "We are delighted to have completed this investment and welcome the Angel CoFund along with other new investors. XF-73 has the potential to become a mainstream treatment for the prevention of SA/MRSA hospital infections and its unique feature of addressing antibiotic resistance can enable the widespread delivery of global patient decolonisation. We look forward to the next stages of developing this drug and to enabling its use in hospitals."

Tim Mills, Investment Director at the Angel CoFund, commented: "Destiny Pharma is exactly the type of business we look to invest in; it is innovative, British and cutting edge in the medical field. This round of investment is for Destiny Pharma's new drug that will kill bacteria via a novel ultra-rapid kill action - designed to even combat antibiotic resistance. We are looking forward to working with the team and supporting them as the company grows."

ENDS

About Destiny Pharma:

Destiny Pharma, a clinical stage pharmaceutical company, was founded in 1997. The Company focuses on the R&D of new antimicrobial drugs, with an emphasis on novel mechanisms of action, which seek to address antibiotic resistance. Through its extensive business network and strategic partnerships Destiny Pharma intends to globally commercialise candidates from the XF Drug platform, which are differentiated by design from traditional antibiotics.

AboutAngel CoFund:

Launched in 2011, the Angel CoFund is a privately run fund that works alongside groups of business angels to invest in high growth small and medium sized businesses across the UK, directly providing funding as well as encouraging the expansion of the business angel market.

Backed by the British Business Bank and the Government's Regional Growth Fund, the £100m Angel CoFund is able to make initial investments of between £100,000 and £1 million into businesses, alongside syndicates of business angels.

To date the fund has supported 42 companies (for example Ventive, Yplan, PlayJam and Micrima) providing over £17 million in direct investment alongside £65 million from business angels and other investors.

www.angelcofund.co.uk

Forward Looking Statement:

This press release contains forward-looking statements that are subject to risks and uncertainties and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Destiny Pharma disclaims any intent or obligation to update forward-looking statements except as required by law.

For further information about Destiny Pharma contact:
Email: pressoffice@destinypharma.com
Tel: +44 (0) 1273 704440

For further information about Angel CoFund contact:
Email: emma@fieldhouseassociates.com
Tel: +44 (0) 7988 696059

July 2014: David Cameron says that superbugs can cast "world back into the dark ages of medicine"

The British Prime Minister David Cameron has called for global action to tackle the growing threat of resistance to antibiotics. The Prime Minister said: "If we fail to act, we are looking at an almost unthinkable scenario where antibiotics no longer work and we are cast back into the dark ages of medicine where treatable infections and injuries will kill once again." The Prime Minister wants Britain to lead the way, using its international leadership and world-class pharmaceutical sector - which employs thousands of highly-skilled experts and is a key part of the country's economy - to battle against antimicrobial resistant infections and bring new drugs to the world market. Mr Cameron has commissioned a wide reaching independent review, co-funded by the world's second largest medical research foundation, the Wellcome Trust, to explore the economic issues surrounding antimicrobial resistance. The review will look at the development, use and regulatory environment of antimicrobials, especially antibiotics, and explore how to make investment in new antibiotics more attractive to pharmaceutical companies and other funding bodies and how governments and other funders can stimulate investment in new antimicrobials and timeframes and mechanisms for implementation. The review will set out a plan for encouraging and accelerating the discovery and development of new generations of antibiotics.

Dr Jeremy Farrar, Director of the Wellcome Trust said: "We are failing to contain the rise of resistance, and failing to develop new drugs to replace those that no longer work. We are heading for a post-antibiotic age". The review will run alongside - and engage closely with - the World Health Organization's development of a Global Action Plan on antimicrobial resistance. The Resolution on Antimicrobial Resistance passed at the World Health Assembly in Geneva in May 2014 recognised the pressing need for the global community to act immediately in the fight to combat increasing resistance.

Around 25,000 people already die each year from infections resistant to antibiotic drugs in Europe alone and the lack of new drugs which are capable of fighting bacteria has been described by the World Health Organization as one of the most significant global risks facing modern medicine. Dr Margaret Chan, Director General of the World Health Organization (WHO) said: "The UK is demonstrating strong leadership in raising awareness about the global threat posed by antimicrobial resistance" and "WHO will work closely with the Review and other key partners on this important initiative."

Dr Bill Love, CEO of Destiny Pharma said: "I am pleased that the British Government have recognised the global threat posed by antibiotic resistance and also identified that the UK is in an ideal position to lead the way in developing novel drugs to combat this threat due to the world-class pharmaceutical expertise that exists in this country. Novel approaches such as the Destiny Pharma drug, XF-73, which is being developed for the prevention of post-surgical Staphylococcal infections caused by drug resistant bacteria are required to ensure that we can combat the threat posed by antibiotic resistance."

April 2014: Destiny Pharma to attend 24th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) Conference in Barcelona, Spain

Destiny Pharma will be attending the 24th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) Conference in Barcelona, Spain between 10 - 13th May. This year's ECCMID will include a series of keynote lectures, symposia, educational workshops and meet-the-expert sessions covering the entire field of infectious diseases and clinical microbiology. Please contact us on info@destinypharma.com if you would like to arrange a meeting during ECCMID.

January 2014: ADAPT Act to Spur Antibiotic Development

New legislation currently being reviewed by the US House of Representatives is aimed at speeding up the approval process for new antibacterial agents. The Antibiotic Development to Advance Patient Treatment Act of 2013 ("ADAPT Act") is a successor to the Generating Antibiotics Incentives Now (GAIN) Act passed by the US Government in 2013 and reinforces the need to advance drug development in order to combat the growing public health threat of "superbugs". The ADAPT Act provides incentives for investment and innovation in developing new antibacterial drugs and is another step forward in developing treatments for patients with antibiotic-resistant infections. Dr Bill Love, CEO of Destiny Pharma said "The GAIN act was the first step towards incentivising pharmaceutical companies to develop new antibacterial drugs and the proposed ADAPT Act takes this a step further by reducing the time it takes to get new antibacterial drugs approved and onto the market. The ADAPT Act demonstrates just how seriously the US Government is taking the threat posed by antibiotic-resistant bacteria and we welcome these developments".

20th December 2013: Destiny Pharma to attend 32nd Annual J.P. Morgan Healthcare Conference, San Francisco

Destiny Pharma today announced that Dr Bill Love, Chief Executive Officer, will be attending the 32nd Annual J.P. Morgan Healthcare Conference, to be held on 13-16th January in San Francisco. If you are attending the conference and would like to book an appointment to meet with Dr Love please email us on kr@destinypharma.com.

18th November 2013: 6th European Antibiotic Awareness Day

The European Antibiotic Awareness Day is an annual European public health initiative that takes place on 18th November to raise awareness about the threat to public health of antibiotic resistance and prudent antibiotic use. The latest data confirms that across the European Union the number of patients infected by resistant bacteria is increasing and that antibiotic resistance is a major threat to public health. For further information about the initiatives that are taking place across Europe please see here.

7th November 2013: Destiny Pharma to attend BioInfect 2013 Conference

Destiny Pharma will be attending the BioInfect 2013 Conference, a major 1-day conference looking at the critical issues relating to the development of new anti-infectives and the endemic problem of resistance on the 26th November at the Alderly Park Conference Centre, Cheshire.

24th September 2013: Report by CDC details today's drug-resistant health threats

The Centers for Disease Control and Prevention (CDC) in the US has in the last week released a landmark report entitled "Antibiotic Resistance Threats in the United States, 2013" which presents for the first time a snapshot of the burden and threats posed by antibiotic-resistant germs having the most impact on human health. As well as identifying methicillin-resistant Staphylococcus aureus (MRSA), the CDC have also identified Vancomycin-resistant Staphylococcus aureus (VRSA) among the three bacteria classified as concerning threats, despite there having only been thirteen cases reported to date.

The report also notes that "whist invasive MRSA infections in healthcare settings appear to be declining...the rates of MRSA infections have increased rapidly among the general population (people who have not recently received care in a healthcare setting)." demonstrating that the problem has now spread out of hospitals into the general community and is a growing problem.

Dr Bill Love, CEO of Destiny Pharma said "The CDC report emphasises just how important antibiotic-resistance is becoming, particularly in the US. Whilst the report rightly focuses on antibiotic-resistant bacteria, the problem of healthcare-associated infections is not limited to bacteria that are antibiotic-resistant and the CDC report highlights that Staphylococcus bacteria, of which MRSA is a sub-population, are one of the most common causes of healthcare-associated infections".

"In fact, recent data by Public Health England (formerly the Health Protection Agency) demonstrated that whist hospital bacteraemia (bacterial infection of the bloodstream) caused by MRSA is slowly decreasing, the number of bacteraemias caused by methicillin sensitive Staphylococcus aureus (MSSA) has remained constant and is now almost tenfold more prevalent than MRSA infections. This is hardly surprising as studies show that about one in three (33%) people carry MSSA in their nose, whilst only two in 100 (2%) people carry MRSA. The potential for further resistance to emerge, particularly outside of the hospital environment is therefore significant and I welcome this report from the CDC"

19th September 2013: UK Government publish strategy to combat antimicrobial resistance between 2013 and 2018

On the 10th September, the UK government published its 5 year antimicrobial strategy document "UK Five Year Antimicrobial Resistance Strategy 2013 to 2018", which stated that there are few public health issues of greater importance than antimicrobial resistance (AMR) in terms of impact on society. The strategy document follows on the heels of the report by the Chief Medical Officer, Professor Dame Sally Davies, who in March warned that the risk posed by antibiotic-resistant bacteria which have the potential to cause infections which are untreatable pose a "catastrophic" threat to the population. In her report Dame Sally noted that "Antimicrobial resistance is a very real threat. If we have no suitable antibiotics to treat infection, minor surgery and routine operations could become high risk procedures".

All of the recommendations on antimicrobial resistance made in the Chief Medical Officer's annual report have been accepted and acted on, including ongoing work to add antimicrobial resistance to the Government's long-term risk register, the National Security Risk Assessment.

The UK Government also moved quickly to announce that the Commons Select Committee for Science and Technology had agreed to hold an enquiry into antimicrobial resistance and that it was already seeking written submissions.

Dr Bill Love, CEO of Destiny Pharma said "Following on so soon from the report by the Chief Medical Officer Dame Sally Davies, the publication of the "UK Five Year Antimicrobial Resistance Strategy 2013 to 2018" document by the Department of Health and DEFRA and the review by the Commons Select Committee for Science and Technology demonstrates just how seriously the UK government is taking the threat of antimicrobial resistance and I believe that this will result in positive public:private partnerships seeking to address the threat posed by antimicrobial resistance"

20th May 2013 Press Release: Part 2 of NIAID-funded US clinical trial of anti-staphylococcal nasal gel XF-73 begins enrollment

Brighton, UK - Clinical stage pharmaceutical company Destiny Pharma today announced the further progression of the Phase I US clinical trial of its lead drug XF-73 to Part 2 of the trial.

Part 1 investigated XF-73's safety, tolerability and distribution, while the forthcoming Part 2 will additionally investigate the efficacy of the drug for nasal decolonization of Staphylococcus aureus (SA) in modified gel formulations when applied for several days under conditions akin to those experienced in hospitals.

The trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), is taking place at the NIAID Phase I Clinical Trials Unit at Case Western Reserve University in Cleveland.

The clinical trial is studying Staphylococcus aureus (SA) decolonization (i.e. the clearance of SA from the nostrils of carriers) as well as safety and tolerability in more than fifty subjects who are treated with XF-73 or placebo. Further information about this clinical trial is available at http://clinicaltrials.gov/ct2/show/NCT01592214.

SA infection remains a worrying complication for hospital admissions. In the US alone it is estimated drug-resistant forms of SA, such as methicillin-resistant SA (MRSA) result in more than 19,000 deaths annually (1), whilst the annual cost of all SA infections in surgical patients is put at $12.3 billion (2).

Nasal decolonization of SA to reduce the risk of infection has been used in many countries and individual institutions, particularly for the patients at risk from MRSA. The continuing problem of bacterial resistance is a significant issue for widespread adoption of nasal decolonization in all patients at risk of SA infection. This is because SA can and already has demonstrated it's ability to generate resistant strains to the main antibiotic (mupirocin) currently used for nasal decolonization. Increased use of the antibiotic might lead to increased prevalence of resistant SA strains which could become dominant.

New guidelines (3) jointly published in February 2013 by the US Surgical Infection Society (SIS), the American Society of Health-System Pharmacists (ASHSP), the Infectious Diseases Society of America (IDSA), and Society for Healthcare Epidemiology of America (SHEA) reflect the benefits that can be seen from extension of nasal decolonization beyond MRSA to all SA strains in higher risk surgeries. At the same time the guidelines highlight the concerns of emergent resistance against mupirocin.

Compared with existing antibiotics, XF-73 has a novel structure and mechanism of action, kills SA rapidly and does not appear to generate resistance in SA (4). It is administered nasally. Its creators at Destiny Pharma believe that these features make it an ideal candidate to widen the scope of SA nasal decolonization beyond the highest risk patient groups to all those at risk who may benefit - a target perhaps unattainable for existing agents due to the existence and fear of resistance development.

Dr Bill Love, CEO of Destiny Pharma commented: "Progression into Part 2 of this important US clinical trial for XF-73 is a significant milestone. The new clinical guidelines underline the need for new therapies that are not associated with a risk of resistance development, something that we obviously believe XF-73 will be able to provide."

XF-73 is a novel dicationic porphyrin with rapid bactericidal activity against Gram-positive bacteria including Staphylococcus aureus (methicillin sensitive and multi-drug resistant strains including MRSA).

References:
1. http://www.cdc.gov/mrsa/statistics/MRSA-Surveillance-Summary.html
2. Noskin GA, et al. National trends in Staphylococcus aureus infection rates. Impact on economic burden and mortality over a 6 year period (1998 -2003). Clinical Infectious Disease, (2007), 45, 1132-40
3. Bratzler et al. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. Am J Health Syst Pharm, (2013),70,195-283 http://www.ashp.org/DocLibrary/BestPractices/TGSurgery.aspx
4. Farrell D, et al. Investigation of the Potential for Mutational Resistance to XF-73, Retapamulin, Mupirocin, Fusidic Acid, Daptomycin, and Vancomycin in Methicillin-Resistant Staphylococcus aureus Isolates during a 55-Passage Study. Antimicrobial Agents and Chemotherapy (2011); 55: 1177-1181

About Destiny Pharma:
Destiny Pharma, a clinical stage pharmaceutical company, was founded in 1997. The Company focuses on the R&D of new antimicrobial drugs, with an emphasis on novel mechanisms of action which seek to address a top 3 global healthcare issue, namely, microbial drug resistance. XF-73 is the Company's lead drug which has completed Phase I clinical development in the UK. Through its extensive business network and strategic partnerships, Destiny Pharma intends to globally commercialise candidates from the XF Drug platform which are differentiated by design from traditional antibiotics.

About the NIH and NIAID:
NIH, the U.S. medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports research-at NIH, within the U.S. and worldwide-to study the causes of infections and immune-mediated diseases and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website at www.niaid.nih.gov.

Forward Looking Statement:
This press release contains forward looking statements that are subject to risks and uncertainties and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Destiny Pharma disclaims any intent or obligation to update forward looking statements except as required by law.

For further information about NIAID, visit www.niaid.nih.gov

For further information about Destiny Pharma contact:
pressoffice@destinypharma.com
Tel: +44 1273 704440

March 2013: Chief Medical Officer Dame Sally Davies publishes annual report providing a comprehensive overview of the threat of antimicrobial resistance and infectious diseases

Dame Sally Davies, the Chief Medical Officer for England has warned that the risk posed by antibiotic-resistant bacteria which have the potential to cause infections which are untreatable pose a "catastrophic" threat to the population in a report published this month. In the report Dame Sally notes that "Antimicrobial resistance is a very real threat. If we have no suitable antibiotics to treat infection, minor surgery and routine operations could become high risk procedures". The report makes 17 recommendations on how this threat should be addressed. Dame Sally also said that pharmaceutical companies should be given encouragement to develop new drugs. Dr Bill Love, CEO of Destiny Pharma said "Dame Sally's report and comments are very timely, as it is important that we do not underestimate the threat posed by antibiotic resistance to healthcare as we know it. I am also very encouraged that Dame Sally also highlighted the need for new drugs to be developed to combat this threat and allow the continued delivery of modern medicine". The Department of Health will soon publish the UK Antimicrobial Resistance Strategy setting out how it will meet the challenge that the Chief Medical Officer has outlined.

February 2013: New US Therapeutic Guidelines on Antimicrobial Prophylaxis published which recommend that all higher risk surgeries should now decolonise all patients with documented colonisation with S. aureus and not just MRSA

New Therapeutic Guidelines on Antimicrobial Prophylaxis were published on the 29th January which were developed jointly by the American Society of Health-System Pharmacists (ASHP), the Infectious Diseases Society of America (IDSA), the Surgical Infection Society (SIS), and the Society for Healthcare Epidemiology of America (SHEA). This work represents an update to the previously published ASHP Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery, as well as guidelines from IDSA and SIS. The guidelines provide practitioners with a standardised approach to the safe, and effective use of antimicrobial agents for the prevention of surgical-site infections (SSIs) based on currently available clinical evidence. The new guidelines recommend that nasal decolonisation of all patients with documented colonisation with S. aureus and not just MRSA should be common practice. This is a significant shift in the advice, as previously only MRSA colonisation was advocated. Dr Bill Love, CEO of Destiny Pharma said "These new guidelines recognise that many more patients are at risk from S. aureus during surgery and that decolonisation can effectively reduce this risk. With widespread adoption of this best surgical practice, antibiotic resistance pressure on existing antibiotics will intensify - highlighting the need for new drugs to deliver, long-term, this highly cost effective intervention".

January 2013: Chief Medical Officer Dame Sally Davies says that antibiotic-resistant diseases pose "Apocalyptic" threat and tells MPs that the issue should be added to the UK Government's national risk register of civil emergencies

Dame Sally Davies, the Chief Medical Officer for England has warned British MPs that the threat posed by antibiotic-resistant diseases pose an "Apocalyptic" threat and could trigger a national emergency on a scale comparable to a catastrophic terrorist attack, major coastal flooding or a pandemic flu outbreak. Dame Sally was appearing in front of the UK House of Commons Science and Technology committee and said that antimicrobial resistance has been put on the Department of Health's risk register and the Department for Environment, Food and Rural Affairs' risk register and would call for the Government to also put antimicrobial resistance on the Government's risk register.

January 2013: US ICU infection rate cut by 44% by Universal bacterial Decolonisation - Hospital Corporation of America (HCA) ICU's to adopt this regimen during early 2013

A recent study involving 43 HCA hospitals consisting of nearly 75,000 patients in 74 adult Intensive Care Units (ICUs) has demonstrated that Universal Decolonisation (using nasal antibiotic and antimicrobial soap on all ICU admissions) resulted in a reduction of the number of patients harbouring MRSA by 37% and a reduction in bloodstream infections by 44%. As a result of this study, the HCA is adopting the use of Universal Decolonisation in all of its adult ICUs and is expected to be completed in early 2013.

17th October 2012: National Institutes of Health launch US clinical trial of XF-73, a new anti-Staphylococcal drug

Scientists have launched an early-stage clinical trial of a novel topical antimicrobial compound known as XF-73 that has shown promise for eliminating Staphylococcus aureus bacteria in the nose, a therapeutic approach that reduces the risk of staph infections. The study is being sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Further details are provided here

July 2012: Generating Antibiotic Incentives Now (GAIN) Act passed by US Senate on 26th June 2012

The "Generating Antibiotic Incentives Now (GAIN) Act provides incentives for pharmaceutical companies to develop new antibiotics/antibacterial drugs for the treatment of life-threatening infections caused by multi-drug resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococcus and enterococcus, Acinetobacter, Klebsiella, Pseudomonas, E. coli, multi-drug resistant Tuberculosis, and Clostridium difficile. Under the GAIN Act Qualified Infectious Disease Products ("QIDPs") intended to treat serious or life-threatening bacterial infections may benefit from the following incentives:

  • 5 Years additional US Market Exclusivity
  • Priority FDA Review reducing from 12 to 8 months
  • Fast Track Status

For further information please click on the link here

26th March 2012 Press Release: IND opens for anti-Staphylococcal drug XF-73 and NIAID-funded US clinical trial begins

Brighton, UK - Clinical stage pharmaceutical company Destiny Pharma today made two important announcements about its lead drug for the prevention of post-surgical Staphylococcal infections, XF-73. The drug has progressed through the Food and Drug Administration (FDA) to an open Investigational New Drug (IND) status and Phase I clinical evaluation is being initiated in the US. The clinical trial is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This latest evaluation follows three successful XF-73 clinical trials in the UK.

The clinical trial will study Staphylococcus aureus (SA) decolonisation as well as safety and tolerability in more than fifty subjects who are treated with XF-73 or placebo. The study will go beyond the UK trials by more accurately simulating patient SA decolonisation, important in mitigating the risk of subsequent SA infection.

Infection remains a worrying complication for hospital admissions. The most common cause of infection is the bacteria Staphylococcus aureus (SA). Methicillin-Resistant Staphylococcus aureus (MRSA) decolonisation is now practiced in many countries, but the continuing problem of bacterial resistance prevents the protection being extended to the larger number of patients who could benefit. There is global need for drugs that can effectively prevent SA infections in patients without succumbing to bacterial resistance. In the US alone it is estimated drug-resistant forms of SA such as MRSA result in 19,000 deaths per year (2). The annual cost of Staphylococcus aureus infection in the US is put at $9.5 billion (3).

Studies to date have shown XF-73 is rapidly bactericidal and has unique abilities to prevent bacterial resistance (1). Its creators at Destiny Pharma believe XF-73 could be used to prevent potentially fatal SA infections, an approach which is becoming compromised due to a limited number of antibiotics and antibiotic-resistance.

NIAID's funding is part of its commitment to explore innovative approaches to the problem of antimicrobial resistance. The Institute uses its clinical research infrastructure to support the evaluation of drugs that may be able to address significant public health needs.

Dr Bill Love, CEO of Destiny Pharma commented: "We're very pleased to have the IND open for XF-73 which is a significant milestone for the Company on the route to the global development of this important new antibacterial drug. We could not have better partners in the form of NIAID and look forward to the next stages of developing this drug and enabling its use in hospitals."

XF-73 is a novel dicationic porphyrin with rapid bactericidal activity against Gram-positive bacteria including Staphylococcus aureus (methicillin sensitive and multi-drug resistant strains including MRSA).

References:
1. Farrell D, et al. Investigation of the Potential for Mutational Resistance to XF-73, Retapamulin, Mupirocin, Fusidic Acid, Daptomycin, and Vancomycin in Methicillin-Resistant Staphylococcus aureus Isolates during a 55-Passage Study. Antimicrobial Agents and Chemotherapy (2011); 55: 1177-1181 No. 3
2. http://www.cdc.gov/mrsa/statistics/MRSA-Surveillance-Summary.html
3. Noskin GA, et al. The burden of Staphylococcus aureus on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide inpatient sample database. Arch Intern Med (2005); 165: 1756-61

About Destiny Pharma:
Destiny Pharma, a clinical stage pharmaceutical company, was founded in 1997. The Company focuses on the R&D of new antimicrobial drugs, with an emphasis on novel mechanisms of action which seek to address a top 3 global healthcare issue, namely, microbial drug resistance. XF-73 is the Company's lead drug which has completed Phase I clinical development in the UK. Through its extensive business network and strategic partnerships, Destiny Pharma intends to globally commercialise candidates from the XF Drug platform which are differentiated by design from traditional antibiotics.

About the NIH and NIAID:
NIH, the U.S. medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports research-at NIH, within the U.S. and worldwide-to study the causes of infections and immune-mediated diseases and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website at www.niaid.nih.gov.

Forward Looking Statement:
This press release contains forward looking statements that are subject to risks and uncertainties and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Destiny Pharma disclaims any intent or obligation to update forward looking statements except as required by law.

For further information about NIAID, visit www.niaid.nih.gov

For further information about Destiny Pharma contact:
Vicky Hoad on +44 7725 554895 or email pressoffice@destinypharma.com
Tel: +44 1273 704440

4th November 2011 Press Release: Sir Nigel Rudd to lead company behind MRSA cure

Sir Nigel RuddSir Nigel Rudd today announced his latest role as Chairman of antimicrobial drug development company Destiny Pharma. The head of BAA and former chief of Boots will lead a newly enhanced Board including Dr David Roblin, former Senior Vice President and Head of Research at Pfizer's European R&D operation.

Founded in 1997 Sussex-based Destiny Pharma has developed a pipeline of drugs designed to avoid the microbial resistance problems associated with traditional antibiotics. Its lead drug, codenamed XF-73, kills antibiotic resistant strains of Staphylococcus aureus (SA)[1] like MRSA without engendering bacterial resistance. Under the leadership of CEO Dr Bill Love successful human trials in the UK[2] recently prompted the U.S. Government's National Institute for Allergies and Infections Diseases (NIAID) to fund clinical evaluations in the USA[3].

The strengthening of the Board of Directors is a sign that Destiny Pharma is preparing for the final stages of developing and commercialising XF-73, its lead product for the prevention of post-surgical Staphylococcal infection; the world's most common cause of hospital bacterial infection. The company estimates XF-73 could save the NHS £7billion over ten years by preventing infections.

With a reputation as a dealmaker Sir Nigel Rudd is an internationally renowned business director. His past and present Chairman roles include £2billion high tech company Invensys, Boots the chemist, car dealer Pendragon and airport operator BAA as well as Deputy Chairman of Barclays. In 2007 Sir Nigel steered Boots through a dramatic takeover, making it the first FTSE 100 company to go private, at a price that exceeded City expectations. He was knighted in 1996 for services to the manufacturing industry.

Sir Nigel's involvement with Destiny Pharma goes back to 2005 when he first invested in the company. His son, venture capitalist Edward Rudd is also an investor. On taking the role the man known as "Britain's busiest Chairman" commented: "I am confident that I can bring my long experience of developing and managing successful companies to the Board of Destiny. The pipeline of anti-microbial agents for the treatment of strains of MRSA will not only form a solid financial base for the company but also has the potential to protect millions of lives worldwide."

References:

[1]. A peer reviewed in vitro passage study conducted in 2008 showed XF-73 was effective against five of the most difficult to treat strains of MRSA even after 55 repeat exposures.
[2]. Destiny Pharma reported successful Phase I clinical trial results for XF-73 at the Interscience Conference on Antimicrobial Agents and Chemotherapy ICAAC) in Boston in September 2010.
[3]. XF-73 was selected for Phase I clinical evaluation by NIAID in August 2011. The study, which will be funded by NIAID, is expected to start in early 2012.

For further information about Destiny Pharma contact:
Vicky Hoad on +44 7725 554895 or email pressoffice@destinypharma.com
Destiny Pharma Limited
Sussex Innovation Centre
Science Park Square
Falmer, Brighton, UK.

15th August 2011 Press Release: Destiny Pharma Lead Drug XF-73 Selected for Clinical Evaluation by U.S. National Institute of Allergy and Infectious Diseases (NIAID)

Brighton, UK - Destiny Pharma Limited, a clinical stage pharmaceutical company focused on combating antimicrobial drug resistance, announced today that its lead drug, XF-73, has been selected for Phase I clinical evaluation by NIAID. XF-73 is under development for the prevention of post-surgical Staphylococcal infections. The collaboration, which will be funded by NIAID, will be conducted under a Clinical Trial Agreement between Destiny Pharma and NIAID.

This award was driven by NIAID's interest in innovative approaches to address antimicrobial resistance and will utilize its clinical research infrastructure to support the clinical evaluation of drugs that have potential to address significant public health needs. The Phase I study of XF-73 will be its first clinical evaluation in the U.S. and will seek to provide safety, tolerability and preliminary anti-Staphylococcal activity of the drug.

XF-73, the lead drug candidate in Destiny's XF Drug portfolio, has demonstrated a unique ability to prevent the emergence of antibacterial resistance (1) as compared to currently available antibiotics. It has also been shown to be potent against a wide range of Staphylococcal strains, including prevalent drug-resistant strains.

XF-73, a novel dicationic porphyrin, has rapid bactericidal activity against Gram-positive bacteria including Staphylococcus aureus, which is the number one global cause of hospital-acquired bacterial infections. The worldwide burden of Staphylococcus aureus infections is considerable. In the U.S. alone, the Centers for Disease Control and Prevention (CDC) estimates that the drug-resistant form of the bacteria Methicillin-Resistant Staphylococcus aureus (MRSA) is responsible for 19,000 deaths per year (2), and the annual cost of Staphylococcus aureus infection is put at $9.5 billion (3).

Dr. Bill Love, CEO, Destiny Pharma commented, "Signing this agreement with NIAID is a significant moment in the development of XF-73, our lead XF Drug. We look forward to working with this world-leading institution and the highly experienced clinical research contractors it brings to initiate XF-73's clinical evaluation in the U.S."

References:
1. Farrell D, et al. Investigation of the Potential for Mutational Resistance to XF-73, Retapamulin, Mupirocin, Fusidic Acid, Daptomycin, and Vancomycin in Methicillin-Resistant Staphylococcus aureus Isolates during a 55-Passage Study. Antimicrobial Agents and Chemotherapy (2011);55: 1177-1181 No. 3
2. http://www.cdc.gov/mrsa/statistics/MRSA-Surveillance-Summary.html
3. Noskin GA, et al. The burden of Staphylococcus aureus on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide inpatient sample database. Arch Intern Med (2005); 165: 1756-61

About Destiny Pharma:
Destiny Pharma, a clinical stage pharmaceutical company, was founded in 1997. The Company focuses on the R&D of new antimicrobial drugs, with an emphasis on novel mechanisms of action which seek to address a top 3 global healthcare issue, namely, microbial drug resistance. XF-73 is the Company's lead drug which has completed Phase I clinical development in the UK. Through its extensive business network and strategic partnerships, Destiny Pharma intends to globally commercialise candidates from the XF Drug platform which are differentiated by design from traditional antibiotics.

About the NIH and NIAID:
The National Institutes of Health (NIH) is the U.S. National Medical Research Agency and includes 27 institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit www.niaid.nih.gov.

The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports research - at NIH, within the U.S. and worldwide - to study the causes of infections and immune-mediated diseases and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website at www.niaid.nih.gov.

Forward Looking Statement:
This press release contains forward looking statements that are subject to risks and uncertainties and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Destiny Pharma disclaims any intent or obligation to update forward looking statements except as required by law.

For further information about NIAID, visit www.niaid.nih.gov

For further information about Destiny Pharma contact:
Vicky Hoad on +44 7725 554895 or email pressoffice@destinypharma.com
Destiny Pharma Limited
Sussex Innovation Centre
Science Park Square
Falmer, Brighton, UK
Tel: +44 1273 704440

September 2010: Destiny Pharma Destiny Pharma present clinical results at the 50th Annual ICAAC Meeting in Boston, USA

Destiny Pharma presented Phase I clinical data at the prestigious 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting meeting held in Boston in September 2010. The results of this Phase I clinical study indicated that increasing concentrations of XF-73 were well tolerated, with few side effects noted, when applied to the noses of healthy subjects. In addition the study was able to show that the two highest concentrations of XF-73 tested were able to either eliminate, or reduce the amount of Staphylococcus aureus in the nostrils, at the end of 5 days treatment. XF-73 is to be developed further to prove how well it works. The aim is to provide a product that can be applied safely to patients about to undergo surgery that will act quickly to reduce the risk of post operative infections caused by S. aureus. Dr Bill Love CEO of Destiny Pharma said "This is an important milestone in the history of the company and has enabled us to publicly discuss our first clinical data on the safety and use of XF-73 in the nasal decolonisation of S. aureus in human volunteers with the leading experts in the field".

September 2010: Destiny Pharma press coverage in the Sunday Express

Destiny Pharma were featured in an article by Lucy Johnson, the Health Editor of the Sunday Express on the 19th September in an article entitled ""New Drug 'A Lifesaver' In War On Superbugs following the recent presentation of clinical data on Destiny Pharma's lead compound XF-73 at this years ICAAC conference in Boston USA

For more news see our News archive.